It's already clear that the story from Amsterdam is that ending epidemic levels of new HIV diagnoses depends on building services and societies that recognize individuals as wonderful, wild, weird, whole people, with more specificity, respect and rigor than ever before. It also depends on activism, nasty women and their male allies, everyone demanding change, refusing to play nice.
- Published
- 26 July 2018
- From
-
AVAC
New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta, Symtuza) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child.
- Published
- 18 July 2018
- From
-
MHRA
The news in May 2018 of a potential risk of neural tube defects in infants born to women taking dolutegravir (DTG) at the time of conception sent shockwaves through the HIV community. But, despite massive global investment, aggressive transition plans – as well as calls for years for more systematic recording of outcomes when women receive ART in pregnancy– few prospective birth registrieshave been established in other settings that can refute or confirm this finding. Meanwhile, women of child-bearing age, whether they intend to become pregnant or not, are being told that they must stick with (or go back to) efavirenz (EFV) – a drug that, before this news, was in the process of being replaced with DTG.
- Published
- 16 July 2018
- From
-
HIV i-Base
A young pregnant woman who switched from dolutegravir (DTG)-based ART, in response to the neural tube defect safety signal, experienced viral rebound on her new regimen. She needed to be switched back to DTG to achieve re-suppression and prevent vertical transmission.
- Published
- 11 July 2018
- From
- HIV i-Base
On 22 June 2018, Janssen issued a Dear Doctor letter (linked below) against using darunavir/cobicistat during pregnancy. This new contraindication is based on significantly reduced plasma levels of darunavir and cobicistat during the second and third trimesters of pregnancy. Darunavir can still be used during pregnancy, but only when boosted by ritonavir.
- Published
- 25 June 2018
- From
- HIV i-Base
In HIV, we pay a lot of attention to parenthood -- but mostly from the perspective of ending mother-to-child transmission. Even then, the public health message is often mostly about the baby, not the health and well-being of the mother.
But almost nowhere do we have deep discussions about reproductive options for HIV-positive men, particularly cisgender straight men.
- Published
- 18 June 2018
- From
-
TheBody.com
At a time when rates of mother-to-child transmission of HIV have plummeted, even in far poorer countries, Nigeria accounted for 37,000 of the world’s 160,000 new cases of babies born with HIV in 2016.
- Published
- 13 June 2018
- From
-
Science
The tools exist. HIV/AIDS can be treated and contained. But in many communities, social, political and economic obstacles get in the way. There, the epidemic is far from over. PBS Newshour reports from Russian, Nigeria and Florida.
- Published
- 12 June 2018
- From
-
PBS NewsHour
Darunavir/cobicistat — marketed as Prezcobix (Janssen) in the United States — should not be given to pregnant women with HIV because of substantially lower exposures of the two medications during pregnancy, the FDA said. The agency updated the label for the once-daily, fixed-dose tablet to reflect the change, which it said was based on data from a small clinical trial involving pregnant women.
- Published
- 11 June 2018
- From
-
Healio (requires free registration)
Aside from worrying about passing HIV on, these mothers tend to prioritise the needs of the family at the expense of their own healthcare on a day-to-day basis
- Published
- 08 May 2018
- From
-
Irish Mirror
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...